BioCentury
ARTICLE | Company News

In Lysando’s Artilysin tech, AiCuris sees means to evade antibiotic resistance

July 9, 2019 7:38 PM UTC

AiCuris believes it can bypass antibiotic resistance by using Lysando's platform to develop an array of phage-derived antibacterial proteins spanning broad and narrow spectrum activity.

AiCuris Anti-infective Cures GmbH (Wuppertal, Germany) will gain exclusive, worldwide rights to develop Artilysins developed by Lysando AG (Triesenberg, Liechtenstein) to treat human Gram-negative and Gram-positive infections, including those associated with pneumonia and cystic fibrosis...

BCIQ Company Profiles

AiCuris Anti-infective Cures AG